---
schema_version: "secwatch.filing_event.v1"
accession: "0001731122-22-002078"
form_type: "8-K"
ticker: "AVXL"
cik: "0001314052"
company_name: "ANAVEX LIFE SCIENCES CORP."
filed_at: "2022-12-02T23:59:59+00:00"
generated_at: "2026-06-21T10:08:14.780673+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Anavex Life Sciences announces positive Phase 2b/3 trial results for ANAVEX2-73 in Alzheimer's disease

## Summary
- Trial met primary endpoints ADAS-Cog and ADCS-ADL with statistically significant results (p=0.033 and p=0.0255).
- Key secondary endpoint CDR-SB also met (p=0.040), showing 27% reduction in clinical decline.
- Patients treated with ANAVEX2-73 were 84% more likely to have improved cognition vs placebo (Odds Ratio=1.84).
- ANAVEX2-73 demonstrated 45% reduction in cognitive decline measured by ADAS-Cog compared to placebo.
- Company plans to meet with regulatory authorities to discuss next steps for approval.

## SEC filing metadata
- accession: 0001731122-22-002078
- form_type: 8-K
- ticker: AVXL
- cik: 0001314052
- company_name: ANAVEX LIFE SCIENCES CORP.
- filed_at: 2022-12-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1314052/000173112222002078/0001731122-22-002078-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1314052/000173112222002078/e4271_8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001731122-22-002078
- JSON: https://secwatch.observer/filing/0001731122-22-002078.json
- Plain text: https://secwatch.observer/filing/0001731122-22-002078.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.